Table 1.
Baseline characteristics
| ICD group (1477), N (%) | Control group (700), N (%) | Total (2177), N (%) | |
|---|---|---|---|
| Female | 269 (18.2) | 127 (18.1) | 396 (18.2) |
| Age (years) | 61.9 (11.5) | 63.5 (11.7) | 62.4 (11.6) |
| BMI (kg/m2) | 27.8 (5.2) | 28.2 (4.9) | 27.9 (5.1) |
| Creatinine (mg/dL) | 1.15 (0.58) | 1.23 (0.61) | 1.18 (0.59) |
| Diastolic blood pressure (mmHg) | 74.0 (11.1) | 75.2 (11.1) | 74.4 (11.1) |
| Haemoglobin | 13.8 (1.8) | 13.8 (1.8) | 13.8 (1.8) |
| Sodium (mmol/L) | 139.1 (3.2) | 139.4 (3.2) | 139.2 (3.2) |
| LVEF (%) | 27.5 (5.5) | 29.1 (5.5) | 28.0 (5.6) |
| QTc (ms) | 441.6 (31.7) | 443.7 (35.3) | 442.3 (32.9) |
| QRS (ms) | 111.8 (20.0) | 114.1 (22.0) | 112.5 (20.7) |
| Diabetes | 443 (30.0) | 215 (30.7) | 658 (30.2) |
| COPD | 170 (11.5) | 68 (9.7) | 238 (10.9) |
| Leading cardiac disease | |||
| Ischaemic cardiomyopathy | 1020 (69.1) | 396 (56.6) | 1416 (65.0) |
| Dilated cardiomyopathy | 457 (30.9) | 304 (43.4) | 761 (35.0) |
| NYHA class | |||
| Class I or II | 927 (62.8) | 394 (56.3) | 1321 (60.7) |
| Class III or IV | 550 (37.2) | 306 (43.7) | 856 (39.3) |
| Tobacco use | 952 (64.5) | 330 (47.1) | 1282 (58.9) |
| Amiodarone | 113 (7.7) | 107 (15.3) | 220 (10.1) |
| AT1 antagonist | 282 (19.1) | 176 (25.1) | 458 (21.0) |
| Beta-blocker | 1397 (94.6) | 655 (93.6) | 2052 (94.3) |
| Loop diuretic | 1035 (70.1) | 536 (76.6) | 1571 (72.2) |
| FU until death or censoring | 2.7 (1.0) | 1.7 (1.2) | 2.4 (1.1) |
| FU until first app. shock, death, or censoring | 2.6 (1.0) | 1.7 (1.2) | 2.3 (1.2) |
| Death | 218 (14.8) | 111 (15.9) | 329 (15.1) |
| First appropriate shock | 105 (7.1) | – | – |
The values are depicted as mean (SD) or counts (percentages).
BMI, body mass index; COPD, chronic obstructive pulmonary disease; FU, follow-up time (years); ICD, implantable cardioverter-defibrillator; LVEF, left ventricular ejection fraction; NYHA, New York Heart Association; QTc, QT-interval corrected by Framingham’s formula; SD, standard deviation.